Published online before print July 6, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Immunology, Cleveland Clinic Foundation, Ohio; and
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio
1Correspondence: NB3-30, Department of Immunology, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195-0001. E-mail: kishd{at}ccf.org
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Key Words: delayed-type hypersensitivity • T regulatory cells • skin • T cell priming
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Contact hypersensitivity (CHS) is a T cell-mediated, inflammatory response of the epidermis to cutaneous sensitization and subsequent challenge with a hapten. Following hapten application or sensitization, epidermal dendritic cells, Langerhans cells (LC), are stimulated to traffic to the skin-draining lymph nodes, where hapten-major histocompatibility complexes (MHC) are presented to and prime specific T cell populations [13 14 15 ]. Challenge of sensitized individuals with the hapten directs primed T cell infiltration into the site of challenge and the activation of the T cells to produce cytokines that mediate the characteristic tissue edema of the response.
In contrast to CD4+ T cell-mediated, classical, delayed-type hypersensitivity responses to protein antigens, hapten-reactive CD8+ T cells are the primary effector cells of CHS responses, which in mice treated with CD8-depleting antibodies and in class I MHC-deficient mice, are low-to-absent, whereas responses in mice treated with CD4-depleting antibodies and in class II MHC-deficient mice, are increased in magnitude and duration [16
17
18
]. In vitro stimulation of purified, hapten-primed CD8+ T cells from lymph nodes of sensitized mice induces interferon-
(IFN-) production, whereas stimulation of CD4+ T cells induces type 2 cytokines, including IL-4, IL-5, and IL-10 but little IFN- [18
, 19
]. Challenge of hapten-sensitized mice normally results in ear-swelling responses, which peak at 24–48 h after challenge and then rapidly decline to background levels. The increased magnitude and extended duration of CHS responses observed in the absence of CD4+ T cells suggest their role as regulators of this response.
The CD4+ T cells mediating regulation of CHS and whether this regulation is directed at the point of T cell priming during sensitization or at elicitation of the response remain unknown. In the current study, the role of IL-2 in the clonal expansion and development of hapten-specific CD4+ and CD8+ T cell populations was investigated. These studies implicate IL-2 and CD4+CD25+ T cells as critical factors regulating the development of hapten-specific CD4+ and CD8+ T cell populations to sensitization as well as the CHS response. These studies demonstrate for the first time the negative regulatory role of IL-2 in the development of effector CD8+ T cell responses to mediate responses to antigens deposited on the skin.
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Antibodies and cytokines
Purified monoclonal antibodies (mAb) YTS 191.1.2 and GK1.5 (anti-mouse CD4) and YTS 169 and TIB-150 (anti-mouse CD8) were purchased from Ligocyte (Bozeman, MT). Culture supernatants of the immunoglobulin G (IgG)-producing hybridomas S4B6 (anti-mouse IL-2) and PC61.5.3 (anti-mouse CD25) were used to purify mAb by protein G chromatography. Polyclonal rat IgG was purchased from Sigma-Aldrich (St. Louis, MO). Fluorescein isothiocyanate (FITC) and phycoerythrin (PE)-labeled mAb specific for CD4, CD8, CD25, CD11a, and rat IgG and capture and detection mAb for IL-2, IL-4, and IFN- were purchased from PharMingen (San Diego, CA).
Hapten sensitization and elicitation of CHS
Mice were sensitized to 2,4-dinitrofluorobenzene (DNFB) by painting the shaved abdomen with 25 µl 0.25% DNFB (Sigma-Aldrich) and with 10 µl on each footpad on days 0 and +1. On day +5, hapten-sensitized and negative control, unsensitized mice were challenged with 10 µl 0.2% DNFB on both sides of each ear. The increase in ear swelling was measured at 24 h intervals after challenge using an engineer’s micrometer (Mitutoyo, Elk Grove Village, IL) and expressed in units of 10–4 in, as previously reported [18
]. The ear-swelling response is presented as the mean increase of each group of four sensitized or nonsensitized mice (i.e., eight ears) ± SEM. Each experiment shown includes its own positive and negative control groups.
In vivo and in vitro depletion of CD4+ and CD8+ T cells
For in vivo depletion of CD4+ T cells, mice were injected with 100 µg each anti-CD4 mAb, YTS 191 and GK1.5, intraperitoneally (i.p.) on 3 consecutive days before hapten sensitization on days 0 and +1 as described previously [18
, 20
]. In vivo depletion of CD8+ T cells was performed by injecting mice with 100 µg each anti-CD8 mAb, YTS 169 and TIB-150. In each experiment, treated, sentinel mice were used to evaluate the efficiency of CD4+ or CD8+ T cell depletion by antibody staining and flow cytometry analysis of spleen and lymph node cells (LNC) and were always >95% when compared with cells from control rat IgG-treated mice. For in vitro depletion of CD4+ or CD8+ T cells, LNC from hapten-sensitized mice were incubated with specific antibody-coated magnetic beads (Dynabeads, Dynal A.S., Oslo, Norway).
Treatment with anti-IL-2 and anti-CD25 antibodies
Mice were injected with 250 µg anti-IL-2 or anti-CD25 mAb (S4B6 or PC61, respectively) on days 0, +1, +2, and +3. As a control, mice were treated with the same amount of rat IgG on the same days.
Enzyme-linked immunospot (ELISPOT) assays for enumeration of hapten-specific T cells producing IFN- and IL-4
ELISPOT assays were performed as described previously [18
, 21
]. Briefly, ELISPOT plates (Whatman Polyfiltronics, Clifton, NJ) were coated with 4 µg/ml IFN--, IL-4-, or IL-2-specific mAb and incubated overnight at 4°C. The plates were blocked with 1% bovine serum albumin in phosphate-buffered saline (PBS) and washed four times with PBS. LNC from unsensitized or DNFB-sensitized mice treated with control IgG, anti-CD25, or anti-IL-2 mAb were prepared on day +5 postsensitization and used as responder cells. Syngeneic spleen cells from naïve mice were labeled with 100 µg/ml 2,4-dinitrobenzene sulfonic acid (DNBS) and treated with 50 µg/ml mitomycin C before use as stimulator cells, which were plated at 5 x 105 cells/well with 2 x 105 or 5 x 105 responder cells/well in serum-free HL-1 medium (BioWhittaker, Walkersville, MD), supplemented with 1 mM L-glutamine and 1 mM antibiotic, as described previously. Responder cells plated with unlabeled splenocytes were used in each assay as a negative (hapten-specificity) control. After 24 h of cell culture at 37°C in 5% CO2, cells were removed from the plate by extensive washing with PBS/0.05% Tween-20 (PBS-T). Biotinylated anti-IFN-, anti-IL-4, or anti-IL-2 mAb (2 µg/ml) was added, and the plate was incubated overnight at 4°C. The following day, the plate was washed three times with PBS-T, and conjugated streptavidin-alkaline phosphatase was added to each well. After 2 h at room temperature, the plates were washed with PBS-T, and nitroblue tetrazolium/5-bromo-4-cholor-30-indolyl substrate (Bio-Rad Laboratories, Hercules, CA) was added for the detection of IFN-, IL-4, or IL-2. The resulting spots were counted with an ImmunoSpot Series I analyzer (Cellular Technology Ltd., Cleveland, OH), which was designed to detect enzyme-linked immunosorbent assay (ELISA) spots with predetermined criteria for spot size, shape, and colorimetric density. The data are shown as the mean number ± SEM of cytokine-producing cells in triplicate cultures after subtraction of spots from control wells containing T cells with unlabeled stimulator cells (always less than five spots/well) for pooled LNC from two mice or for LNC from two individual mice as indicated.
Stimulation of hapten-primed CD4 and CD8 T cells to produce cytokines in culture
As stimulator cells, hapten-presenting LC (hpLC) were purified from LNC suspensions of DNFB-sensitized mice on day +1 following hapten sensitization using positive selection with anti-CD11c, mAb-coated magnetic beads (Miltenyi Biotec, Auburn, CA). As responder cells, CD4+- or CD8+-enriched cell populations were prepared from LNC from unsensitized or DNFB-sensitized mice on day +4 following hapten sensitization. Aliquots of 2.5 x 105 T cell populations were cultured in a 96-well plate with 5 x 104 hpLC in RPMI medium supplemented with 10% heat-inactivated fetal calf serum (FCS) and 5 mM L-glutamine at 37°C in 5% CO2. After 36 h of culture, supernatants were collected and tested for concentrations of IL-2, IL-4, and IFN- by sandwich ELISA (R&D Systems, Minneapolis, MN), according to the manufacturer’s protocol. Results are reported as concentration of cytokine produced in pg/ml culture supernatant ± SEM.
Flow cytometry analyses
LNC were prepared from naïve mice or from hapten-sensitized mice on day +3 or +4 postsensitization. The cells were washed twice with staining buffer (Dulbecco’s PBS with 2% FCS/0.2% NaN3), and 1 x 106 cell aliquots were incubated on ice in 150 µl rat serum (Rockland, Gilbertsville, PA), diluted 1:1000 in the staining buffer. After 30 min, the cells were washed twice and stained with fluorochrome-labeled anti-mouse mAb (in these studies, CD25-, CD44-, CD11a-, CD4-, and CD8- or rat IgG-specific mAb were used) at 10 µg/ml. After 30 min on ice, the cells were washed five times, resuspended in staining buffer, and analyzed by two-color flow cytometry using a FACScan and CellQuest software (Becton Dickinson, San Jose, CA). Sample data were collected on 20,000-gated cells.
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
 View larger version (13K): [in a new window] |
Figure 1. Antigen-specific CD8+ T cells are the primary source of IL-2 during sensitization for CHS. (A) C57BL/6 mice were sensitized with 0.25% DNFB on days 0 and +1. On day +5 after sensitization, LNC suspensions were prepared from sensitized and naïve mice. CD4+ (open bars) and CD8+ (solid bars) T cell-enriched populations were cultured with DNBS-labeled or unlabeled syngeneic splenocytes on anti-IL-2 mAb-coated ELISPOT plates. After 24 h, cells were removed, and the ELISPOT assay was developed to detect IL-2-producing T cells. The mean number ± SEM of IL-2-producing CD4+ or CD8+ T cells per 2 x 105 cells in triplicate cultures for pooled LNC from two mice is shown after subtraction of spots from control wells containing T cells with unlabeled stimulator cells (less than five spots per well). Results are representative of two individual experiments. *, P< 0.005, compared with the number of spots in sensitized CD4+ and naïve CD8+ T cell cultures using Student’s t-test. (B) BALB/c mice were sensitized with 0.25% DNFB on days 0 and +1. On day +4, LNC suspensions were prepared from groups of four sensitized and naïve mice and pooled. CD4+ and CD8+ T cell-enriched populations were cultured with hpLC. After 36 h, culture supernatants were tested by ELISA to determine IL-2, IL-4, and IFN- production. The mean concentration ± SEM of IL-2, IL-4, and IFN- produced by naïve and hapten-primed CD4+ and CD8+ T cells in triplicate cultures is shown. Detectable cytokine production was not observed when the enriched T cell populations were cultured in the absence of the hpLC (data not shown). *, P < 0.005, compared with cytokine production in all other groups for each specific cytokine using Student’s t-test. ND, Not detected.
|
(Fig. 1B)
. Culture with hpLC failed to stimulate detectable production of IL-4 or IFN- by naïve CD4+ or CD8+ T cells and low amounts of IL-2 production by naïve CD8+ but not CD4+ T cells. As previously shown, hapten-primed CD8+ but not CD4+ T cells produced IFN- during stimulation in culture, and hapten-primed CD4+ but not CD8+ T cells produced IL-4 [18, 19]. Consistent with the ELISPOT results, hapten-primed CD4+ T cells produced low amounts of IL-2, whereas hapten-primed CD8+ T cells produced fivefold more during culture with the hpLC. Cytokine production observed by all test T cell populations required stimulation with hpLC, as no detectable cytokine production was observed when the enriched T cell populations were cultured in the absence of the hpLC (data not shown).
CD8+ T cells do not express CD25 during hapten sensitization
To begin to examine the potential role of IL-2 in the expansion of hapten-specific CD4+ and CD8+ T cells during sensitization for CHS, the expression of CD25 was compared on T cells from groups of five naïve and DNFB-sensitized mice on day +4 after sensitization. Expression of CD25 was observed on CD4+ T cells from naïve (8.45±0.74% of total CD4+ T cells) and DNFB-sensitized (11.67±0.74%) mice. In contrast, CD8+ T cell expression of CD25 was low-to-absent in naïve (3.34±0.98%) mice and did not increase during sensitization (3.74±0.98%). Representative flow cytometry data from one mouse in each group are shown in Figure 2
. Analysis of CD8+ T cells on days +2 and +3 after hapten sensitization also indicated no increase in CD25-expressing cells (data not shown).
 View larger version (54K): [in a new window] |
Figure 2. CD4 + T cells and not CD8+ T cells express CD25 during sensitization for CHS. Groups of five BALB/c mice were sensitized with 0.25% DNFB on days and 0 and +1. On day +4 postsensitization, LNC suspensions from naïve and sensitized mice were stained with FITC-anti-CD25 mAb and PE-anti-CD4 or -CD8 mAb. Cells from representative animals are shown, and the percentages of CD4+ or CD8+ cells expressing CD25 in the CD4+ or CD8+ T cell populations are indicated in the upper right-hand quadrants. The mean percentage for each group of five animals ± SEM is indicated in the text.
|
 View larger version (34K): [in a new window] |
Figure 3. Expression of CD11a on CD4+ or CD8+ T cells from mice treated with anti-IL-2 mAb during sensitization for CHS. Groups of four BALB/c mice were sensitized with 0.25% DNFB on days 0 and +1 and were treated with control rat IgG or with anti-IL-2 mAb on days 0, +1, +2, and +3. On day +4, LNC suspensions from naïve and sensitized mice were stained with FITC-anti-CD11a mAb and PE-anti-CD4 or anti-CD8 mAb. Cells from a representative animal are shown, and the percentages of CD4+ or CD8+ cells expressing CD11a in the gated CD4+ or CD8+ T cell populations are indicated in the upper right-hand quadrants. The mean percentage for each group ± SEM is indicated in Table 1
.
|
|
View this table: [in a new window] |
Table 1. Treatment with Anti-IL-2 mAb during Hapten Sensitization Increases CD11ahigh/CD8+ T Cells in Skin-Draining Lymph Nodesa
|
 View larger version (41K): [in a new window] |
Figure 4. Treatment with anti-CD25 mAb does not delete CD4+ T cells expressing CD25. BALB/c mice were sensitized to 0.25% DNFB on days 0 and +1 and treated with 250 µg anti-CD25 mAb i.p. on days 0, +1, +2, and +3. On day +4, LNC suspensions were prepared and stained to detect the presence of CD25 and rat IgG on CD4+ T cells. Cells from representative animals are shown, and the percentages of CD4+ cells staining positively for CD25 and rat IgG in the CD4+ T cell populations are indicated in the upper right-hand quadrants. The mean percentage for each group of three mice ± SEM is indicated in the text.
|
 View larger version (11K): [in a new window] |
Figure 5. Treatment with anti-IL-2 or anti-CD25 mAb during sensitization increases the magnitude and duration of CHS responses and the development of antigen-specific T cells producing IFN- and IL-4. Groups of four BALB/c mice were sensitized with 0.25% DNFB on days 0 and +1 and challenged with 0.2% DNFB on day +5. One group of mice was treated with 250 µg control rat IgG ( ) i.p. on days 0, +1, +2, and +3 during DNFB sensitization, and this group is shown as the positive control (A–C), and each experimental group was tested at the same time. The increase in ear swelling in sensitized and naïve, nonsensitized ( ) mice was measured at 24 h intervals postchallenge and is expressed in 10–4 in ± SEM. (A) Mice were treated with 250 µg anti-IL-2 mAb ( ) i.p. on days 0, +1, +2, and +3 during DNFB sensitization. *, P < 0.02, using Student’s t-test. (B) Mice were treated with 250 µg anti-CD25 mAb () i.p. on days 0, +1, +2, and +3 during DNFB sensitization. *, P< 0.001. (C) Mice were given 200 µg anti-CD4 mAb () i.p. on days –3, –2, and –1 and then sensitized with 0.25% DNFB on days 0 and +1 and challenged on the ears with 0.2% DNFB. *, P < 0.01.
|
-producing cells and CD4+ IL-4-producing cells were compared in the lymph nodes of animals treated with control IgG, anti-IL-2, or anti-CD25 mAb during sensitization. On day +5 postsensitization, LNC suspensions were separated into CD4+- or CD8+-enriched cell populations using magnetic beads and tested in ELISPOT assays to enumerate the number of hapten-specific cells producing cytokines. Hapten-specific CD8+ T cells producing IFN- were detected in lymph nodes of sensitized (70 spots/2x105 cells) but not naïve mice (Fig. 6A
). Consistent with the elevated ear-swelling responses, LNC from mice treated with anti-IL-2 (110 spots/2x105 cells) or anti-CD25 mAb (183 spots/2x105 cells) contained more hapten-specific CD8+ T cells producing IFN- than the control IgG-treated group. Consistently, the numbers of hapten-specific CD4+ T cells producing IL-4 in the lymph nodes of DNFB-sensitized mice were not increased significantly by treatment with anti-IL-2 or anti-CD25 mAb during sensitization (Fig. 6B)
.
 View larger version (11K): [in a new window] |
Figure 6. Treatment with anti-IL-2 or anti-CD25 mAb during sensitization increases the numbers of hapten-specific CD8+ T cells and CD4+ T cells producing cytokines in DNFB-sensitized mice. BALB/c mice were sensitized with 0.25% DNFB on days 0 and +1. Mice were treated during sensitization with control rat IgG, anti-IL-2, or anti-CD25 mAb as above. On day +5 after sensitization, CD8+ T cell-enriched populations were prepared from lymph nodes and cultured with DNBS-labeled or unlabeled syngeneic splenocytes on anti-IFN- mAb-coated ELISPOT plates. CD4+ T cell-enriched populations were cultured on anti-IL-4 mAb-coated plates. After 24 h, cells were removed, and the ELISPOT assay was developed to enumerate hapten-specific and IFN-- and IL-4-producing T cells. The mean number ± SEM of (A) IFN--producing CD8+ T cells and (B) IL-4-producing CD4+ T cells in triplicate cultures for pooled LNC from two mice is shown after subtraction of spots from control wells containing T cells with unlabeled stimulator cells. Results are representative of two individual experiments. *, P < 0.05, using Student’s t-test, in comparison with LNC from sensitized, IgG-treated, control mice. ND, Not detected.
|
. Consistent with the increased CHS response, depletion of CD4+ T cells prior to hapten sensitization increased the numbers of IFN--producing cells when compared with control-treated, sensitized mice. However, the number of hapten-specific cells producing IFN- did not increase further when the mice depleted of CD4+ cells were treated additionally with anti-CD25 mAb (Fig. 7
). Thus, anti-CD25 mAb-mediated enhancement of effector CD8+ T cell development for CHS was dependent on CD4+ T cells.
 View larger version (9K): [in a new window] |
Figure 7. Anti-CD25 mAb treatment does not increase hapten-specific CD8+ T cell development in the absence of CD4+ T cells. BALB/c mice were given 200 µg control, rat IgG, or anti-CD4 mAb i.p. on days –3, –2, and –1 and were sensitized with 0.25% DNFB on days 0 and +1. Groups of the mice were treated during sensitization with control rat IgG or anti-CD25 mAb as above. On day +5 after sensitization, CD8+ T cell-enriched populations were prepared and tested for numbers of hapten-specific, IFN--producing cells. Results are representative of two individual experiments. *, P < 0.04, in comparison with sensitized, IgG-treated, control mice. ND, Not detected.
|
 View larger version (9K): [in a new window] |
Figure 8. Anti-CD25 mAb treatment increases hapten-specific T cell production of IL-4 in the absence of CD8+ T cells. BALB/c mice were given 200 µg control rat IgG or anti-CD8 mAb i.p. on days –3, –2, and –1 and were sensitized with 0.25% DNFB on days 0 and +1. Groups of CD8-depleted mice were treated during sensitization with control rat IgG or anti-CD25 mAb as above. On day +5 following sensitization, LNC suspensions were prepared and tested for numbers of hapten-specific, IL-4-producing cells. Results are representative of two individual experiments. *, P < 0.05, in comparison with sensitized IgG-treated control mice. ND, Not detected.
|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-producing CD8+ T cells, which are the primary effector cells of the response to hapten challenge, and populations of CD4+ T cells, which produce type 2 cytokines including IL-4 and IL-5 [18
, 19
]. In contrast to antiviral responses, CD8+ T cells did not express CD25 during development for CHS responses. The absence of CD25 expression on hapten-primed CD8+ T cells may indicate that these T cells do not develop to express cytolytic function during elicitation of CHS. However, cytolysis of keratinocytes and hapten-labeled spleen cell targets by hapten-primed CD8+ T cells in vitro has been observed in some laboratories but not in others [27
28
29
]. The goal of the current study was to investigate the influence of IL-2 in the expansion of hapten-reactive T cell populations during sensitization for CHS. It is surprising that the number of hapten-specific CD8+ T cells producing IL-2 was almost tenfold greater than IL-2-producing CD4+ T cells, and hapten-primed CD8+ T cells produced much more IL-2 during in vitro stimulation with hpLC than did hapten-primed CD4+ T cells. These results indicate that CD8+ T cells are the major source of IL-2 during CD4+ and CD8+ T cell priming to DNFB sensitization. The IL-2 production and effector functions of hapten-specific CD4+ and CD8+ T cells during priming for CHS responses are distinct from these aspects of CD4+ and CD8+ T cell function in many other immune responses including antiviral and classical delayed-type hypersensitivity responses.
The expression of CD25 on CD4+ but not CD8+ T cells during hapten priming led us to predict that treatment with antagonizing antibodies to IL-2 or to CD25 would inhibit the development of hapten-specific, type 2, cytokine-producing CD4+ T cells but not the IFN--producing effector CD8+ T cells. Treatment with either antibody enhanced the development of hapten-specific CD8+ T cells producing IFN- and hapten-specific CD4+ T cells producing IL-4. Furthermore, treatment with either antibody during hapten sensitization resulted in CHS responses of higher magnitude and longer duration, which correlated with the enhanced development of the effector CD8+ T cell compartment. Recent studies from this laboratory have shown that the increased numbers of hapten-specific CD8+ T cells in CD4-depleted animals are a result of increased expansion of these T cells in the lymph nodes rather than an increase in frequency in the absence of CD4+ T cells [30
].
The enhancement of hapten-specific CD4+ and CD8+ T cell development in anti-IL-2 mAb-treated mice indicated that IL-2 is not a critical growth factor for these T cell populations. The enhanced development of hapten-specific CD8+ T cells and elicited CHS responses in mice treated with anti-IL-2 or anti-CD25 mAb suggested that the antibodies neutralized a regulatory component of the response and were reminiscent of the absence of regulation observed in mice depleted of CD4+ T cells during hapten sensitization. Our previous observations that hapten-specific CD4+ T cells develop to IL-4- and IL-5-producing cells [18 ] led us to suspect that type 2 cytokines produced by the CD4+ T cells were regulating CD8+ T cell development and the CHS response. However, enhanced CD8+ T cell responses observed in anti-IL-2 or anti-CD25 mAb-treated mice were coincident with enhanced IL-4-producing CD4+ T cell development. These results suggest that the CD4+ T cells regulating CD8+ T cell development and CHS are not likely to be the hapten-specific CD4+ T cells producing IL-4 and that a common CD4-mediated mechanism regulates the development of hapten-specific CD4+ and CD8+ T cell populations during sensitization. The results further suggest that IL-2 is not a growth factor for the hapten-specific CD4+ or CD8+ T cell populations but plays a critical role in down-regulating the development of these T cell populations and the CHS response.
The current results indicate that a primary point of regulation in the CHS response is the CD4+CD25+ T cell-mediated restriction of effector CD8+ T cell development to sensitization, and this limits the magnitude and duration of the swelling/inflammation elicited by hapten challenge. In other immune responses, regulation mediated by CD4+CD25+ T cells may be expressed during elicitation of the response by suppressing the function of the effector T cells. For example, recent studies by Belkaid and co-workers [31 ] have indicated the accumulation of CD4+CD25+ T cells at infection sites of experimental leishmaniasis and the down-regulation of ongoing immune responses to eliminate the parasite. Whether the CD4+CD25+ regulatory T cells that restrict hapten-reactive CD8+ T cell development also function in down-modulating ongoing ear-swelling responses at the antigen challenge site is untested.
In summary, the current report indicates that IL-2 is an important factor in the regulation of effector CD8+ T cell priming and the CHS response. The role of IL-2 is not mediated directly at the level of hapten-specific CD4+ and CD8+ T cell development during sensitization as a growth factor. Rather, IL-2 is required to maintain the presence and activity of CD4+CD25+ T cells that restrict the development of effector CD8+ T cells and in turn, the magnitude and duration of the CHS response. The results of this study have further exposed the complexity of the cells induced to mediate and regulate CHS responses. Hapten sensitization primes populations of hapten-specific, IFN--producing CD8+ T cells, which are the effector cells of the CHS response as well as hapten-specific, IL-4-producing CD4+ T cells, whose function in the response remains unclear. Although the function of the CD4+CD25+ regulatory T cells is dependent on IL-2, the hapten specificity and other requirements to elicit the regulatory function of these cells are undefined currently. Clarification of these requirements should increase understanding of these regulatory cells and the ability to enhance or inhibit CD8+ T cell-mediated responses to antigens deposited in the skin.
Received February 4, 2005; revised April 15, 2005; accepted May 20, 2005.
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
production during lymphocytic choriomeningitis virus infection J. Immunol. 155,5690-5699[Abstract]
ß T lymphocytes for apoptosis Nature 353,858-861[CrossRef][Medline]-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases J. Immunol. 155,1151-1164[Abstract] producing (Tc1) effector CD8+ T cells and IL-4/Il-10 producing (Th2) negative regulatory CD4+ T cells J. Exp. Med. 183,1001-1012This article has been cited by other articles:
 |
|
 |
|
  B. Jux, S. Kadow, and C. Esser Langerhans Cell Maturation and Contact Hypersensitivity Are Impaired in Aryl Hydrocarbon Receptor-Null Mice J. Immunol., June 1, 2009; 182(11): 6709 - 6717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Kish, A. V. Gorbachev, and R. L. Fairchild Regulatory function of CD4+CD25+ T cells from Class II MHC-deficient mice in contact hypersensitivity responses J. Leukoc. Biol., July 1, 2007; 82(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
